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Somatic mutations of the BRAF gene are common in melanomas and nevi but the contribution of polymorphisms in
this gene to melanoma or nevus susceptibility remains unclear. An Australian melanoma case–control sample was
typed for 16 single nucleotide polymorphisms (SNP) within the BRAF gene, and ﬁve SNP in three neighboring
genes. The sample comprised 755 melanoma cases from 740 families stratiﬁed by family history of melanoma and
controls from 635 unselected twin families (2239 individuals). Ancestry of the cases and controls was recorded, and
the twins had undergone skin examination to assess total body nevus count, degree of freckling, and pigmentation
phenotype. Genotyping was carried out via primer extension followed by matrix-assisted laser desorption ioni-
zation-time of ﬂight mass spectrometry. SNP in the BRAF gene were found to be weakly associated with melanoma
status but not with development of nevi or freckles. The estimated proportion of attributable risk of melanoma due
to variants in BRAF is 1.6%. This study shows that BRAF polymorphisms predispose to melanoma but the causal
variant has yet to be determined. The burden of disease associated with this variant is greater than that associated
with the major melanoma susceptibility locus CDKN2A, which has an estimated attributable risk of 0.2%.
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The field of cancer genetics has produced notable suc-
cesses applying genetic linkage analysis to identify genes
that confer significant inherited susceptibility to particular
cancers that show specific familial clustering. So far, these
have been variants in genes of relatively large effect but
which are rare in the general population, e.g., BRCA1 and
BRCA2 in breast cancer and CDKN2A in melanoma, and
thus do not account for a major contribution to overall pop-
ulation risks. Unlike these prominent cases it seems likely
that most common cancers with an inherited component
involve more genes, each conferring a fraction of the risk,
and perhaps particular variants in multiple genes acting
epistatically. Clearly, these are not readily amenable to dis-
covery using the linkage approach and instead an associ-
ation design may be more successful (Barrett et al, 2005).
Thus far, such association studies have had mixed results,
arguably due to inadequate sample size and suboptimal
study design (Risch, 2001). Here, we present a large asso-
ciation study of the role in genetic predisposition to me-
lanoma susceptibility of the BRAF gene, in a systematic and
comprehensive haplotyping approach across the entire lo-
cus and adjacent genes.
The Ras/Raf/MAPK (mitogen-activated protein kinase)
pathway is a critical molecular signaling cascade through
which extracellular signals can be transmitted into the nu-
cleus to regulate cell proliferation or differentiation through
altered gene expression. Constitutive activation of this
pathway is a frequent event in melanoma development
(Cohen et al, 2002; Dong et al, 2003; Satyamoorthy et al,
2003). Recently, BRAF gene somatic mutations have been
shown to be associated with malignant melanoma (Davies
et al, 2002), being present in 40%–88% of cutaneous me-
lanomas (Brose et al, 2002; Davies et al, 2002; Dong et al,
2003; Gorden et al, 2003; Kumar et al, 2003; Pollock et al,
2003; Satyamoorthy et al, 2003), whereas being essentially
absent in control tissues. Mutations are also extremely
common (74%–82%) in benign melanocytic nevi (Pollock
et al, 2003; Yazdi et al, 2003), an observation arguing for a
critical role for B-Raf in initiating melanocytic neoplasia.
All somatic mutations documented to date in melanoma
have been found in the kinase domain of B-Raf, encoded by
exons 11 and 15 of the BRAF gene (Brose et al, 2002; Da-
vies et al, 2002; Pollock et al, 2003; Satyamoorthy et al,
2003; Casula et al, 2004) (Fig 1). The vast majority (over
90%) of these mutations affect codon 599 and result in a
valine to glutamic acid substitution, see note added in proof
which is thought to lead to constitutive activation of Ras/
Raf/MAPK signal transduction (Davies et al, 2002). Other
less frequent BRAF coding somatic mutations in melanoma
are G468A in exon 11 and L596V and Q608H in exon 15
(Davies et al, 2002; Pollock et al, 2003; Casula et al, 2004).
In some melanomas without BRAF mutations, the MAPK
pathway is constitutively activated through mutation of
NRAS (van Elsas et al, 1996). BRAF and NRAS mutations
appear to have similar effects in melanoma development1These authors contributed equally to this work.
Abbreviations: BTNS, Brisbane Twin Nevus Study; CMM, cutane-
ous malignant melanoma; QFMP, Queensland Familial Melanoma
Project; SNP, single nucleotide polymorphism
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
1252
since their presence in any single tumor is mutually exclu-
sive (Brose et al, 2002; Davies et al, 2002; Pollock et al,
2003; Satyamoorthy et al, 2003). This situation is similar in
lung (Brose et al, 2002; Davies et al, 2002; Naoki et al, 2002),
colon (Davies et al, 2002; Rajagopalan et al, 2002; Yuen
et al, 2002), and thyroid cancers (Kimura et al, 2003), where
BRAF and RAS mutations are rarely found together.
To date, only one common germline BRAF coding variant
has been reported, a synonymous G642G change
(rs1042179 (NCBI, 2003)). Although this particular variant
was not tested, Meyer et al (2003b) recently described a
case–control study (502 melanoma cases; 450 controls)
assessing possible associations between intronic single
nucleotide polymorphisms (SNP) in the BRAF gene and
melanoma risk. Six of 12 SNP analyzed in this German
case–control study were significantly (po0.05) more com-
mon in male cases than controls, but none of the SNP were
significantly associated with melanoma risk in females, or
when both sexes were combined. By contrast, Laud et al
(2003) found no association between BRAF coding and in-
tronic variants in a panel of 80 melanoma cases and 91
controls. More recently, a study of 569 Italian cases has
revealed two types of germline variants (Casula et al, 2004),
which were previously unreported codon changes (M116R,
Q608H; note this was misreported as G608H (Casula et al,
2005)). The latter falls in exon 15 near the hotspot for so-
matic mutations that affect the kinase domain of the protein,
whereas the former is of uncertain functional significance.
One instance of the V599E substitution in germline DNA has
subsequently been retracted (Casula et al, 2005).
In this study, we sought to test the hypothesis that in-
herited polymorphisms of the BRAF gene predispose to the
development of melanoma using a large case–control study.
In addition, we attempted to detect association with nevus
count and freckling phenotype in the general population.
Results
After data cleaning (Materials and Methods), there were 755
CMM (cutaneous malignant melanoma) cases with geno-
type information, and 46 unaffected genotyped relatives
from the QFMP (Queensland Familial Melanoma Project).
From the BTNS (Brisbane Twin Nevus Study), there were
2229 controls with genotype information after data cleaning
and removal of one of each pair of the 159 monozygotic
(MZ) twins. For the case–control analyses, there were 720
unrelated cases (mean age 52.9 y, 43.8% male) and 1170
unrelated controls (mean age 42.6 y, 44.8% male). We and
others (Martin et al, 1997; Risch, 2001) have shown that
unselected twin collections provide valid population con-
trols since they represent a truly random proportion (1% of
all births) of the general population. Previously, we reported
no differences in mole counts between the twins and the
general population from Queensland (Zhu et al, 1999, 2004).
Over 95% of grandparents of both cases and controls are of
Northern European ancestry, mainly from the British Isles.
Mean Breslow thickness of melanomas in cases was
0.3 mm, and 21.4% were histologically graded as level I
tumors.
All 16 SNP minor alleles were more common in cases
than in controls, and the differences in frequency were sta-
tistically significant for 11 SNP (exceeding a critical thresh-
old of 0.05, uncorrected for multiple testing; see Table I)
After correction for multiple testing, the best individual SNP
permutation in p-value was 0.065. No SNP was significantly
associated with melanoma when either males or females
were considered separately, and indeed, there was no het-
erogeneity of risk between sexes. The highest genotypic
relative risk was for the B11 SNP (rs1639679) in intron 11
(1.30, 95% CI¼ 1.00–1.69, p¼0.018). Adjusting for ances-
try (proportion of grandparents born in the British Isles) did
not alter the strength of this association.
The B5 (rs1267621) SNP minor allele frequency was
highest in the high familial risk cases (Table I), and a test for
trend in family risk was significant (p¼0.008). In the 10
cases (from eight high-risk families) carrying a mutation in
CDKN2A, the major familial melanoma predisposition gene,
none carried the rare allele (Table II).
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Figure 1
Positions of single nucleotide polymorphisms (SNP) within the
BRAF gene. Each of the 18 exons is indicated by a box in the center of
the figure, with the exon number adjacent to the right. Domains of the
gene encoding the three conserved regions found among Raf family
members are indicated by differential shading. SNP are shown by their
unique database id (rs#) and the abbreviation used in this paper (B#).
Other SNP in this study that flank BRAF are shown in Fig 2.
BRAF POLYMORPHISMS AND MELANOMA RISK 1253125 : 6 DECEMBER 2005
The 16 BRAF SNP were in extremely tight linkage disequi-
librium (LD), such that D0 values for pairs of adjacent SNP
ranged from 0.72 to 1 (Fig 2). This degree of LD results in only
three haplotypes defining 98% of chromosomes (Table III).
The strength of association of the common haplotypes com-
bining the BRAF SNP was not greater than that evidenced by
the individual SNP with melanoma (Table IV). For example,
SNP B5, or equivalently, the ‘‘C’’ haplotype, accounted for
a proportion attributable risk estimated as 1.6% (95%
CI¼ 0.1%–3.1%). The histological level and Breslow thick-
ness of tumors were not correlated with genotype, either for
individual SNP or overall haplotype (Table IV).
There was no association between any of the BRAF SNP
and counts of total, macular, papular, or atypical nevi in the
Australian controls (best p-value¼ 0.16; see Table V). Sim-
ilarly, no association was seen with freckling (Table V).
Numbers of genotypes containing the ‘‘C’’ haplotype were
not large, however.
Table I. SNP genotyped around the BRAF gene
Gene SNP ID dbSNP_ID Exon/introna
Change (transcribed
strand) Frequencyb
Association v2
with melanoma p-value
MRPS33 M1 rs1533933 C4G 0.205 1.29 0.525
BRAF B1 rs765373 Promoter C4T 0.138 4.32 0.116
B2 rs7810757 50UTR A4G 0.073 1.32 0.517
B3 rs1267621 Intron-1 G4A 0.133 5.41 0.067
B4 rs1267606 Intron-2 T4G 0.061 4.24 0.120
B5 rs1267601 Intron-2 A4G 0.061 9.79 0.007
B6 rs1267609 Intron-3 G4A 0.060 7.02 0.030
B7 rs1267649 Intron-5 C4G 0.061 7.02 0.030
B8 rs1639675 Intron-7 T4C 0.061 9.07 0.011
B9 rs1267636 Intron-8 A4G 0.061 6.88 0.032
B10 rs1267646 Intron-9 C4T 0.135 4.17 0.124
B11 rs1639679 Intron-11 C4A 0.060 7.11 0.029
B12 IVS12-48CT Intron-12 C4T 0.062 2.59 0.274
B13 rs1267639 Intron-13 C4T 0.062 9.04 0.011
B14 rs1267638 Intron-13 T4C 0.062 6.97 0.031
B15 rs1042179 Exon-16 A4G 0.140 6.6 0.037
B16 rs3789806 Intron-16 C4G 0.141 6.71 0.035
ADCK2 A1 rs1046515 C4T 0.061 6.63 0.036
Q9ULE3 Q1 rs269238 T4G 0.290 3.39 0.184
Q2 rs3748088 C4T 0.337 4.16 0.125
Q3 rs4726882 A4C 0.500 1.58 0.453
aWithin the 18 exon transcript ENST00000288602.
bMinor allele frequency in controls.
SNP, single nucleotide polymorphism.
Table II. Association analysis. Increased gradient of BRAF association with familial risk of melanoma
Population group C/C C/A A/A Minor allele frequency p-value
Controls (n¼ 1170) 0.874 0.123 0.003 0.064
Low familial risk (n¼ 448) 0.859 0.127 0.013 0.077 0.041
Intermediate familial risk (n¼150) 0.900 0.073 0.027 0.063 0.002
High familial risk (n¼ 59) 0.780 0.220 0.000 0.110 0.099
CDKN2A mutation families (n¼ 8) 1.000 0.000 0.000 0.000 0.614
Genotypic frequencies of the B2 SNP in the Australian case–control sample stratified by familial risk class and CDKN2A mutation status.
SNP, single nucleotide polymorphism.
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Discussion
The question of whether germline coding region mutations
of the BRAF gene are responsible for predisposition in large
multiple-case melanoma families has been investigated by
several groups. The answer appears to be that such large
impact mutations are not responsible for any significant
proportion of familial or sporadic melanoma since no germ-
line exon 15 BRAF mutations have been found after screen-
ing of 42 familial and two sporadic melanoma cases (Lang
et al, 2003); 46 familial melanoma cases, 21 multiple me-
lanoma cases, and 106 sporadic melanoma cases (Meyer
et al, 2003a); 35 familial melanoma cases, 16 multiple me-
lanoma cases, 18 uveal melanoma cases, and 11 probands
from familes with melanoma nervous system tumors (Laud
et al, 2003), respectively. Most recently, however, a germline
variant, Q608H, in exon 15 has been found (Casula et al,
2004; Casula et al, 2005) though its functional significance is
unknown. Nevertheless, as 569 CMM cases were screened,
the low incidence (0.18%) of these mutations cannot play a
major role in melanoma susceptibility.
In a similar vein, a recent study by Laud et al (2003)
suggested that BRAF is also not a low-risk susceptibility
gene for melanoma. This group screened the entire coding
region of BRAF for germline mutations in melanoma-prone
families and sporadic cases (n¼80). They found 13 variants
(four silent exonic and nine intronic), but none segregated in
melanoma-prone families, and there were no significant
differences in heterozygote frequencies between cases and
controls for any of the 13 SNP. In stark contrast, the results
of our study and that of Meyer et al (2003b) suggest that
BRAF is indeed a low-risk susceptibility gene for melanoma.
There are several plausible reasons for the discrepant re-
sults found between these studies. Laud et al analyzed a
much smaller number of samples (n¼80) compared to our
study, in which 753 cases were utilized. The larger data
set provides more power to detect SNP frequency differ-
ences, particularly if allele frequency differences are small
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Figure 2
Linkage disequilibrium across
484 kb. Plot of inter-single nucleo-
tide polymorphism (SNP) linkage
disequilibrium, measured as Le-
wontin’s D0, using Haploview (Bar-
rett et al, 2005). Gene intron
(boxes) and exon (tick marks) po-
sitions are represented along the
X-axis, whereas SNP positions are
shown as vertical dotted lines. SNP
abbreviations are given in Table I.
Table III. Frequency of BRAF haplotypes and association with CMM risk, adjusted for mole count, hair, and skin color
Haplotypea
Frequency
Odds ratio
(95% CI) p-value1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
A C A G T A G C T A C A C C T A C 0.854 1.00
B T G A T A G C T A T A T C T G G 0.072 1.07 (0.78–1.46) 0.68
C T A A G G A G C G T C C T C G G 0.059 1.24 (0.89–1.73) 0.21
Other – – – – – – – – – – – – – – – – 0.016 1.13 (0.461–2.75) 0.79
aSNP numbering according to Table I (1¼B1, etc.).
CMM, cutaneous malignant melanoma; SNP, single nucleotide polymorphism.
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yet significant. In addition, for each SNP, Laud et al calcu-
lated heterozygote frequencies and determined that there
were no significant differences in frequencies between ca-
ses and controls for any SNP analyzed. In our study, in
addition to genotype frequencies, allele frequencies were
determined for cases and controls, and for three SNP lo-
cated in BRAF, significant differences in frequencies be-
tween cases and controls were found, suggesting BRAF is a
melanoma predisposition gene. A similar conclusion was
reached by Meyer et al (2003b), who found six SNP in BRAF
were associated with melanoma risk in male cases
(n¼ 470), although not female cases (n¼530), or males
and females combined. The SNP B11 (rs1639679) and B5
(rs1267601) were associated with melanoma susceptibility
in both the Australian and German case–control populations
(see Table I).
The number of haplotypes spanning the 175 kb BRAF
locus is surprisingly limited. In passing, the observed
haplotypes exhibited what has been described as a ‘‘yin–
yang’’ phenomenon (Zhang et al, 2003), in that the ‘‘C’’
haplotype differs at every site from the most common ‘‘A’’
haplotype. The causal variant(s) associated with melanoma
risk is as yet unknown. As noted earlier, given the substan-
tial sequencing of all exons and exon–intron junctions (Laud
et al, 2003; Casula et al, 2004) it seems unlikely that there
are any undiscovered coding changes common enough to
account for our results. Newly described SNP in the pro-
moter region are also unlikely to be relevant (Jackson et al,
2005).
The hitherto best known melanoma genetic risk factor,
CDKN2A, accounts for about 25% of familial melanoma
cases (Pollock and Trent, 2000), but less than 0.2% of the
total melanoma burden (Aitken et al, 1999; Tsao et al, 2000).
Based on the observed genotype frequencies, we estimate
that BRAF could account for a proportion attributable risk to
develop melanoma of 1.6% in the Australian population.
Our results suggest that, in addition to the high somatic
mutation rate of BRAF in melanomas and nevi, germline
polymorphisms in this gene also predispose to melanoma,
although not to the development of nevi or freckles.
One would expect that if germline BRAF mutations are
associated with increased risk of melanoma, then a similar
strength of relationship with cutaneous nevus count would
also be observed. We did not observe such a relationship
with heterozygotes carrying the ‘‘C’’ haplotype, and there
were only eight C/C homozygotes in the entire dataset,
yielding little power, suggesting that there may be multiple
independent pathways to the different phenotypes. We
were not surprised by the lack of association between
BRAF genotype and freckling, since an overlap in the
mechanisms giving rise to freckling and to melanoma is less
likely.
Materials and Methods
Participants We studied an Australian case-control sample made
up of 755 melanoma cases from 740 families participating in the
QFMP (Aitken et al, 1994; Aitken et al, 1996; Palmer et al, 2000),
and genotyped controls were 2239 individuals without melanoma
from 635 twin families (476 DZ, 159 MZ) enrolled in the BTNS (Zhu
et al, 1999, 2004). For purposes of a case–control analysis of me-
lanoma, we used a subsample comprising 720 genotyped me-
lanoma cases (one per family) and 1170 unrelated genotyped
controls (parents of the twins individuals) used in calculations as
indicated below. Ancestry of the cases and controls was recorded
(grandparental country of birth and ethnicity), along with pheno-
typic risk factors such as hair and eye color, and tanning type.
Tumor thickness and level were recorded for the cases that
included both in situ and invasive melanomas. A familial risk index
was generated for the cases using a permutation-based procedure
as described elsewhere (Aitken et al, 1994). From this, three familial
risk levels (‘‘low’’ (or ‘‘sporadic’’), ‘‘intermediate,’’ and ‘‘high’’) were
classified that correspond approximately to having zero, one, or
two or more first degree relatives affected with melanoma. These
were used to further stratify the cases in terms of genetic risk.
Only clinically verified cases among relatives were included in the
analysis.
Table IV. Association of BRAF haplotypes with melanoma, and
with tumor thickness (mm) among cases
BRAF
genotypea Odds ratio (95% CI)
Breslow thickness
(95% CI)
A/A 1.00 (reference) 0.61 (0.54–0.69)
A/B 1.07 (0.80–1.42) 0.69 (0.52–0.86)
A/C 0.94 (0.69–1.29) 0.61 (0.43–0.78)
B/B 0.71 (0.15–2.57) 0.74 (0.00–1.85)
B/C 1.24 (0.41–3.60) 0.24 (0.00–0.94)
C/C 5.80 (1.40–39.07) 0.62 (0.03–1.21)
aBased on haplotypes given in Table III.
TableV. Association of BRAF haplotypes with nevus counts and freckling scores in adolescent twin controlsa
BRAF
genotypeb
Number
genotyped
Median total nevus
count (95% CI)
Median papular
nevus count (95% CI)
Mean freckling
score (95%CI)
A/A 822 106 (101.9–110.1) 17 (15.8–18.1) 2.6 (2.4–2.8)
A/B 144 102 (92.0–111.9) 17 (14.6–19.4) 2.6 (2.1–3.1)
A/C 110 104 (94.0–113.9) 19.5 (16.6–22.4) 2.4 (1.9–3.0)
B/B 76 82 (63.2–100.8) 7 (1.6–12.4) 0.5 (3.0 to 4.0)
B/C 12 68 (28.1–107.9) 10.5 (5.0–16.0) 4.1 (2.4–5.9)
C/C 1 242 41 2 (3.0 to 7.0)
aNo differences between genotypes are significant at the 5% level.
bBased on haplotypes given in Table III.
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Standard melanoma risk factors, including propensity to burn in
the sun, pigmentation (skin color, hair color at 21 y, eye color, total
freckling in summer, and density of melanocytic nevi) were ob-
tained by mailed questionnaire with intensive telephone follow-up.
Hair color was recorded as either black, dark brown, light brown,
fair, or red/auburn and skin color was recorded as fair, medium, or
olive/dark. A three-point scale was also used for eye color, includ-
ing the categories blue/gray, green/hazel, and brown. Total freck-
ling in summer was self-reported as either nil, 1–100, or 101þ , and
density of melanocytic nevi was estimated using a scale of nil, few,
moderate, or many.
Skin color (on a three-point scale), hair color (on a five-point
scale), and eye color (on a three-point scale) is therefore available
for most of the cases and controls. Although nevus counts were
only carried out in the adolescents, self-assessed nevus number
on a four-point scale (‘‘none,’’ ‘‘few,’’ ‘‘moderate,’’ ‘‘many’’) is avail-
able for parents of the adolescents, as well as the melanoma
cases.
Additional analyses of mole count has been performed using
the BTNS twins and their siblings closest in age who have all un-
dergone total body skin examination at age 12 y by a trained nurse
who assessed nevus count, degree of freckling, and pigmentary
phenotypes (Zhu et al, 1999). Parents of the twins were genotyped,
but only self-reported pigmentary characteristics are available,
employing identical measures to those used to record these char-
acteristics in the melanoma individuals. A four-point scale, how-
ever, was used to record freckle density, including no freckling, a
few, some, and many freckles. No members of the BTNS had been
diagnosed with melanoma at the time of this study. Approval to
undertake this study was granted by the Human Research Ethics
Committee of the Queensland Institute of Medical Research. All
participants gave their signed informed consent. Australian Na-
tional Health and Medical Research Council encompassing the
Declaration of Helsinki Guidelines for human research were ad-
hered to.
Genotyping Fifteen intronic/promoter and 1 exonic BRAF SNP
were typed chosen on the basis of polymorphism in our collection
and distribution across the gene (Table I, Fig 1). In order to define
flanking areas where linkage disequilibrium decayed around the
175 kb BRAF gene region we also typed five SNP in three flanking
genes (MRPS33, ADCK2, and Q9ULE3), which extended an ad-
ditional 232 and 77 kb on either side and spanning 484 kb in total.
SNP identity and type is given in Table I; full sequence and other
linked information may be found in the public databases by using
the unique ‘‘rs’’ accession number (NCBI, 2003). Genotyping was
performed via a primer extension reaction and matrix-assisted la-
ser desorption ionization-time of flight mass spectrometry (Mass-
ARRAY, Sequenom, San Diego, California) as previously described
(Bansal et al, 2002; James et al, 2004). All SNP had dropout rates
ofo0.5%. Data cleaning involved examining Mendelian inconsist-
encies, departures from Hardy–Weinberg Equilibrium, and discor-
dances between MZ pairs. After examination, where the Mendelian
errors were encountered the entire family was dropped from anal-
ysis. Error rates due to genotyping technical causes, estimated by
replicate typing and use of 159 MZ twin pairs, were found to be
0.11%–0.2%, respectively.
Statistical analysis The use of the BTNS families as controls
greatly increases our ability to detect genotyping problems, but
makes the analysis more complex. We have extracted unrelated
cases and controls, and performed multiple logistic regression
analysis versus individual SNP, and Fisher–Irwin Exact tests com-
paring genotype counts in cases and controls. Correction for mul-
tiple testing versus individual SNP was done by repeatedly
permuting cases and controls, retaining the best text statistic out
of 21 tests from each of 100,000 replicates. Given that this is a
replication of a previously reported association it is not necessary
to apply a genome-wide level correction. Haplotypic association
analysis was performed using the haplo.stat package (Lake et al,
2002) running in R (RDCG, 2004), cross-checking with the COCA-
PHASE program (Lang et al, 2003). These programs use an EM
algorithm to enumerate all legal haplotypes that could give rise to
an observed genotype and estimate the posterior probabilities for
these haplotypes for each individual. Association is then assessed
via binomial (or ordinal logistic or linear) regression using the ha-
plotype probabilities as weights. This approach allows covariates
to be easily included. Proportion attributable risk was calculated
using the control genotype frequencies and the estimated geno-
typic odds ratios (PAR¼ 11/(p2g2þ 2p(1p)g1þ (1p)2), where p
is the risk allele frequency, and g2 and g1 the genotypic relative
risks for risk allele homozygotes and heterozygotes).
Note added in proof
NCBI-Genbank has renumbered Braf codons such that the
previous 599 is now 600.
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